BioSpace News Archive

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced the first patient implant in a U.S. Food and Drug Administration clinical study that will evaluate the safety and effectiveness of the M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion for the treatment of contiguous two-level symptomatic cervical radiculopathy.

Arcturus Therapeutics Holdings Inc. announced an agreement with Vinbiocare Biotechnology Joint Stock Company, a member of Vingroup Joint Stock Company, regarding a collaboration to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines, for sale and use within Vietnam.

The Lupus Research Alliance is particularly excited about the U.S. Food and Drug Administration approval of anifrolumab-fnia, a first in class, type I interferon receptor antagonist, indicated for adults with moderate to severe systemic lupus erythematosus.

Immunovant, Inc. today announced that it has received a $200 million strategic investment from Roivant Sciences.

Minerva Neurosciences, Inc. today reported key business updates and financial results for the quarter ended June 30, 2021.

Strongbridge Biopharma plc today announced that the definitive joint proxy statement/prospectus of Strongbridge (the “Proxy Statement”), which also constitutes a scheme circular under Irish law, is being sent as of July 30, 2021 to Strongbridge shareholders.

Cerecor Inc. today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation.

Todd R. Patrick to retire; Board of Directors appoints Brian Varnum, Ph.D., current President and Chief Development Officer, as new Chief Executive Officer

Celcuity Inc. today announced that it will release its financial results for the second quarter 2021 after the stock market close on Monday, August 9, 2021.

Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in upcoming investor conferences in August.